Trial Profile

A First in human study assessing safety and pharmacokinetics and define a RP2D of INV-1120

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INV-1120 (Primary)
Indications Colorectal cancer; Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
Sponsors Shenzhen Ionova Life Sciences Co., Ltd.

Most Recent Events

06 Jul 2023 Status changed from recruiting to completed according to result presented at the 59th Annual Meeting of the American Society of Clinical Oncology
06 Jul 2023 New trial record
06 Jun 2023 Results of Preliminary safety, efficacy, and pharmacokinetics (PK) results of the EP4 antagonist INV-1120 from a phase I study in Chinese patients with advanced solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com